BioCentury | Sep 26, 2016
Clinical News

Subcutaneous XmAb7195: Phase Ib started

...Xencor began a U.S. Phase Ib trial of once-weekly subcutaneous XmAb7195 in about 62 healthy volunteers and...
...volunteers and patients with atopic disease. An open-label part will compare 4 dose levels of subcutaneous XmAb7195...
...in 30 healthy volunteers. A double-blind, placebo-controlled part will then evaluate 4 dose levels of subcutaneous XmAb7195...
Items per page:
1 - 1 of 1